<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychol Med</journal-id><journal-id journal-id-type="iso-abbrev">Psychol Med</journal-id><journal-id journal-id-type="publisher-id">PSM</journal-id><journal-title-group><journal-title>Psychological Medicine</journal-title></journal-title-group><issn pub-type="ppub">0033-2917</issn><issn pub-type="epub">1469-8978</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28558859</article-id><article-id pub-id-type="pmc">5647681</article-id><article-id pub-id-type="doi">10.1017/S0033291717001222</article-id><article-id pub-id-type="pii">S0033291717001222</article-id><article-id pub-id-type="publisher-id">00122</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Acute memory and psychotomimetic effects of cannabis and tobacco both &#x02018;joint&#x02019;
and individually: a placebo-controlled trial</article-title><alt-title alt-title-type="left-running">C. Hindocha et al.</alt-title><alt-title alt-title-type="right-running">Cannabis and tobacco interactions</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hindocha</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Freeman</surname><given-names>T. P.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>J. X.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shaban</surname><given-names>N. D. C.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Curran</surname><given-names>H. V.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Clincial Psychopharmacology Unit</addr-line>,
<institution>University College London</institution>, <addr-line>Gower St,
London</addr-line>, <country>UK</country></aff><aff id="aff2"><label>2</label><institution>The Sophie Davis School of Biomedical Education,
The City College of New York</institution>, <addr-line>NY</addr-line>,
<country>USA</country></aff><author-notes><corresp id="cor1"><label>*</label>Address for correspondence: C. Hindocha,
<addr-line>Clinical Psychopharmacology Unit</addr-line>, <institution>University College
London</institution>, <addr-line>Gower St</addr-line>, <addr-line>London WC1E
6BT</addr-line>, <country>UK</country>. (Email: <email>c.hindocha@ucl.ac.uk</email>)</corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>31</day><month>5</month><year>2017</year></pub-date><volume>47</volume><issue>15</issue><fpage>2708</fpage><lpage>2719</lpage><history><date date-type="received"><day>13</day><month>1</month><year>2017</year></date><date date-type="rev-recd"><day>07</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>07</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; Cambridge University Press 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Cambridge University Press</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article, distributed under the terms of the Creative
Commons Attribution licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits
unrestricted re-use, distribution, and reproduction in any medium, provided the original
work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0033291717001222a.pdf"/><abstract abstract-type="normal"><sec id="sec_a1"><title>Background</title><p>Cannabis and tobacco have contrasting cognitive effects. Smoking cannabis with tobacco
is prevalent in many countries and although this may well influence cognitive and mental
health outcomes, the possibility has rarely been investigated in human experimental
psychopharmacological research.</p></sec><sec id="sec_a2" sec-type="methods"><title>Method</title><p>The individual and interactive effects of cannabis and tobacco were evaluated in 24
non-dependent cannabis and tobacco smokers in a randomized, placebo-controlled,
double-blind, 2 (cannabis, placebo) &#x000d7; 2 (tobacco, placebo) crossover design. Verbal
memory (prose recall), working memory (WM) performance including maintenance,
manipulation and attention (N-back), psychotomimetic, subjective and cardiovascular
measures were recorded on each of four sessions.</p></sec><sec id="sec_a3" sec-type="results"><title>Results</title><p>Cannabis alone impaired verbal memory. <italic>A priori</italic> contrasts indicated
that tobacco offset the effects of cannabis on delayed recall. However, this was not
supported by linear mixed model analysis. Cannabis load-dependently impaired WM. By
contrast, tobacco improved WM across all load levels. The acute psychotomimetic effects
and ratings of &#x02018;stoned&#x02019; and &#x02018;dizzy&#x02019; induced by cannabis were not altered by tobacco.
Cannabis and tobacco had independent effects on increasing heart rate and interacting
effects on increasing diastolic blood pressure.</p></sec><sec id="sec_a4" sec-type="conclusion"><title>Conclusions</title><p>Relative to placebo, acute cannabis impaired verbal memory and WM. Tobacco enhanced
performance on WM, independently of cannabis. Moreover, we found some preliminary
evidence that tobacco may offset the effects of cannabis on delayed, but not immediate,
verbal recall. In contrast, the psychotomimetic and subjective effects of cannabis were
unaffected by tobacco co-administration. By reducing the cognitive impairment from
cannabis, tobacco co-administration may perpetuate use despite adverse health
consequences.</p></sec></abstract><kwd-group><title>Key words</title><kwd>Cannabis</kwd><kwd>co-administration</kwd><kwd>drug-interaction</kwd><kwd>marijuana</kwd><kwd>memory</kwd><kwd>psychosis</kwd><kwd>tobacco</kwd></kwd-group><counts><fig-count count="4"/><table-count count="1"/><ref-count count="66"/><page-count count="12"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Cannabis and tobacco, two of the world's most commonly used drugs, are frequently
co-administered together in &#x02018;joints&#x02019; or &#x02018;spliffs&#x02019; (Hindocha <italic>et al.</italic>
<xref rid="ref32" ref-type="bibr">2016</xref>). Delta-9-tetrahydrocannabinol (THC) and
nicotine, respectively are these drugs primary psychoactive components. Cannabinoid
receptors (CB1R) and nicotine acetylcholine receptors (nAChRs) are both densely populated in
the hippocampus and the amygdala, suggesting a potential neurobiological overlap (Herkenham
<italic>et al.</italic>
<xref rid="ref31" ref-type="bibr">1990</xref>; Picciotto <italic>et al.</italic>
<xref rid="ref52" ref-type="bibr">2000</xref>) for the effects of these two drugs on memory.
This is evident behaviourally as THC and nicotine have opposite effects on memory and
cognition in humans with THC impairing and nicotine facilitating performance (Gray
<italic>et al.</italic>
<xref rid="ref25" ref-type="bibr">1996</xref>; Levin &#x00026; Simon, <xref rid="ref42" ref-type="bibr">1998</xref>; Curran <italic>et al.</italic>
<xref rid="ref9" ref-type="bibr">2002</xref>; D'Souza <italic>et al.</italic>
<xref rid="ref14" ref-type="bibr">2004</xref>; Levin <italic>et al.</italic>
<xref rid="ref41" ref-type="bibr">2006</xref>; Morrison <italic>et al.</italic>
<xref rid="ref50" ref-type="bibr">2009</xref>; Heishman <italic>et al.</italic>
<xref rid="ref30" ref-type="bibr">2010</xref>; Bossong <italic>et al.</italic>
<xref rid="ref4" ref-type="bibr">2012</xref>). Preclinical data suggest a relationship
between the endocannabinoid system and the cholinergic system. Full or partial agonists of
the CB1R, including THC, increase nicotine conditioned place preference (Valjent <italic>et
al.</italic>
<xref rid="ref63" ref-type="bibr">2002</xref>) and self-administration (Gamaleddin
<italic>et al.</italic>
<xref rid="ref23" ref-type="bibr">2012</xref>) whereas antagonists at this receptor (e.g.
rimonabant) decrease these behaviours (Le Foll &#x00026; Goldberg, <xref rid="ref40" ref-type="bibr">2004</xref>; Cohen <italic>et al.</italic>
<xref rid="ref6" ref-type="bibr">2005</xref>; Forget <italic>et al.</italic>
<xref rid="ref20" ref-type="bibr">2005</xref>; Shoaib, <xref rid="ref59" ref-type="bibr">2008</xref>). Further nicotine and THC both interact with mesolimbic dopaminergic
pathways potentially modulating reward-related processes in addiction (Rowell <italic>et al.</italic>
<xref rid="ref56" ref-type="bibr">1987</xref>; Fernandez-Ruiz <italic>et al.</italic>
<xref rid="ref18" ref-type="bibr">2010</xref>).</p><p>Acutely, cannabis produces a profile of cognitive impairment, similar to that associated
with schizophrenia, and particularly in the realms of working and episodic memory (Fletcher
&#x00026; Honey, <xref rid="ref19" ref-type="bibr">2006</xref>; Broyd <italic>et al.</italic>
<xref rid="ref5" ref-type="bibr">2016</xref>; Curran <italic>et al.</italic>
<xref rid="ref10" ref-type="bibr">2016</xref>). Deficits in episodic memory are some of the
most robust findings reported (Crane <italic>et al.</italic>
<xref rid="ref8" ref-type="bibr">2013</xref>). Dose-dependent (Hart <italic>et al.</italic>
<xref rid="ref27" ref-type="bibr">2010</xref>) effects of THC on working memory are also
consistently reported (Hunault <italic>et al.</italic>
<xref rid="ref34" ref-type="bibr">2009</xref>; Ramaekers <italic>et al.</italic>
<xref rid="ref55" ref-type="bibr">2009</xref>) and are specifically related to the
manipulation rather than the maintenance of information. Nicotine, in contrast, improves
memory in both smokers and non-smokers (Heishman <italic>et al.</italic>
<xref rid="ref30" ref-type="bibr">2010</xref>). It has been hypothesised that tobacco might
compensate for some of the negative effects of cannabis (Rabin &#x00026; George, <xref rid="ref53" ref-type="bibr">2015</xref>). In support of this, individuals smoking cannabis
and cigarettes have less episodic memory impairment when drug free compared with cannabis
users alone (Schuster <italic>et al.</italic>
<xref rid="ref57" ref-type="bibr">2015</xref>), but experience worse cognitive withdrawal
symptoms from tobacco in regards to episodic and working memory (Jacobsen <italic>et al.</italic>
<xref rid="ref35" ref-type="bibr">2007</xref>). Moreover, an ecological momentary assessment
study found that when cannabis and tobacco are combined, working memory performance was
better in comparison with cannabis alone (Schuster <italic>et al.</italic>
<xref rid="ref58" ref-type="bibr">2016</xref>). However, to our knowledge, no controlled
studies have examined whether tobacco can offset the cognitive impairing effects of
cannabis.</p><p>Importantly, epidemiological research has implicated both cannabis and tobacco as
independent risk factors for psychosis (Moore <italic>et al.</italic>
<xref rid="ref48" ref-type="bibr">2007</xref>; Gurillo <italic>et al.</italic>
<xref rid="ref26" ref-type="bibr">2015</xref>). It is clear that both cigarette smoking and
problematic cannabis use are highly prevalent in people with schizophrenia in
epidemiological research (De Leon &#x00026; Diaz, <xref rid="ref11" ref-type="bibr">2005</xref>; Koskinen <italic>et al.</italic>
<xref rid="ref37" ref-type="bibr">2010</xref>). However, it can be extremely challenging to
dissociate the role of cannabis from tobacco in these studies due to the high co-occurrence
of their use both i.e. cannabis users are more likely to smoke cigarettes, and cannabis and
tobacco are often combined into joints and smoked together (Gage <italic>et al.</italic>
<xref rid="ref22" ref-type="bibr">2014</xref>). Acutely, cannabis/THC induces psychotic-like
effects, including paranoia, disorganised thinking and hallucinations. However, there is no
such experimental evidence that nicotine/tobacco induces or exacerbates psychotic- symptoms
acutely. One study investigated the acute effect of a nicotine patch on cannabis induced
psychotomimetic effects (using the Addiction Research Center Inventory: LSD subscale) where
nicotine had no effect on THC (Penetar <italic>et al.</italic>
<xref rid="ref51" ref-type="bibr">2005</xref>). However, this study lacks the ecological
administration method of &#x02018;joints&#x02019; and did not use a scale specific to the psychotomimetic
drug effects (Mason <italic>et al.</italic>
<xref rid="ref44" ref-type="bibr">2008</xref>). Thus, given the high prevalence of use of
cannabis and tobacco, it is necessary to understand the interactive effects on
psychotic-like symptoms induced by cannabis.</p><p>This study, therefore, aimed to investigate the individual and combined effects of cannabis
and tobacco on episodic and working memory, and psychotic-like experiences. We hypothesised
that tobacco would acutely counteract the negative effects of cannabis on working and
episodic memory and will directly test with an <italic>a priori comparison of</italic> the
combination of cannabis&#x000a0;+&#x000a0;tobacco and cannabis alone. We also hypothesised that cannabis
would increase psychotic-like symptoms; how nicotine would influence these was exploratory
given the dearth of previous relevant research.</p></sec><sec id="sec2"><title>Methods and materials</title><sec id="sec2-1"><title>Design and participants</title><p>A randomised double-blind, placebo-controlled, four-way, crossover trial was used to
evaluate the acute effects of cannabis and tobacco, both alone and combined (<xref ref-type="table" rid="tab01">Table 1</xref>). Participants attended four sessions,
separated by at least 1-week washout (as this is &#x000a0;&#x02a7e;&#x000a0;3 times elimination half-life of THC)
(D'Souza <italic>et al.</italic>
<xref rid="ref15" ref-type="bibr">2008</xref>; Hindocha <italic>et al.</italic>
<xref rid="ref33" ref-type="bibr">2015</xref>). Washout of nicotine was confirmed by
Carbon Monoxide (CO) &#x02a7d;&#x000a0;6 (Bedfont Micro Smokerlyser, Bedfont Scientific Ltd, Bedfont, UK).
Order of treatment was determined by a balanced Latin square. All participants provided
written, informed consent on each occasion. Ethical approval was given by the UCL Ethics
Committee. <table-wrap id="tab01" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Cannabis and tobacco doses in the study drug and their matched placebos (see <xref ref-type="fig" rid="fig01">Fig. 1</xref>)</p></caption><alternatives><graphic xlink:href="S0033291717001222_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Drug</th><th align="left" rowspan="1" colspan="1">Condition</th><th align="left" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr><td rowspan="2" valign="top" colspan="1">Cannabis</td><td rowspan="1" colspan="1">Active</td><td rowspan="1" colspan="1">66.67&#x000a0;mg Bedrobinol (16.1% THC and &#x0003c;1%
CBD)</td></tr><tr><td rowspan="1" colspan="1">Matched placebo</td><td rowspan="1" colspan="1">66.67&#x000a0;mg Placebo (derived from Bedrocan; 0.07%
THC)</td></tr><tr><td rowspan="2" valign="top" colspan="1">Tobacco</td><td rowspan="1" colspan="1">Active</td><td rowspan="1" colspan="1">311&#x000a0;mg Marlboro Red (15.48&#x000a0;mg nicotine, 16&#x000a0;mg tar,
0.8&#x000a0;mg nicotine yield)</td></tr><tr><td rowspan="1" colspan="1">Matched placebo</td><td rowspan="1" colspan="1">311&#x000a0;mg denicotinized tobacco (Magic 0, 0.04&#x000a0;mg/g
nicotine)</td></tr></tbody></table></alternatives></table-wrap></p><p>Medically and psychiatrically healthy, non-dependent but experienced, cannabis and
tobacco users were recruited. A flowchart of participant recruitment can be found in the
online Supplementary Materials (see online Supplementary Fig. S2).</p></sec><sec id="sec2-2"><title>Power calculation</title><p>Power was informed by a previous four-way crossover trial examining interactive effects
of THC and Cannabidiol (CBD) (<italic>d</italic>&#x000a0;=&#x000a0;0.5; based on a <italic>t</italic> test
of THC&#x000a0;+&#x000a0;CBD attenuating negative effects of THC (Hindocha <italic>et al.</italic>
<xref rid="ref33" ref-type="bibr">2015</xref>)). This estimated a sample size of 24
participants with complete data would achieve power of <italic>d</italic>&#x000a0;=&#x000a0;0.5 to detect
such effects with an alpha of 0.05 (G*power version 3.1.9.2) (Faul <italic>et al.</italic>
<xref rid="ref17" ref-type="bibr">2007</xref>). This was also appropriate for completely
balancing the order of the four treatments completed the study as 24&#x000a0;=&#x000a0;4 factorial.</p></sec><sec id="sec2-3"><title>Inclusion criteria</title><p>Inclusion criteria were: (i) age 18&#x02013;60 years, (ii) regular (&#x02a7e;&#x000a0;once per month and &#x000a0;&#x02a7d;&#x000a0;3
times a week) use of cannabis and tobacco in joints for the last 6 months, (iii)
self-reported (SR) ability to smoke one whole &#x02018;standard&#x02019; joint, (iv) normal or
corrected-to-normal vision, (v) fluent English, (vi) SR abstinence from tobacco, cannabis,
alcohol and other drugs for &#x02a7e;&#x000a0;12&#x000a0;h prior to each session, (vii) alveolar CO &#x02a7d;&#x000a0;6&#x000a0;ppm to
confirm no recent smoking on each test day (Cooper &#x00026; Haney, <xref rid="ref7" ref-type="bibr">2009</xref>). Exclusion criteria were (i) scoring &#x02a7e;&#x000a0;3 on the cannabis
Severity of Dependence Scale (SDS; Gossop <italic>et al.</italic>
<xref rid="ref24" ref-type="bibr">1995</xref>), (ii) treatment-seeking for cannabis,
tobacco use, or currently using nicotine replacement therapy or other cessation
pharmacotherapy; (iii) smoking &#x02a7e;&#x000a0;10 cigarettes a day or scoring &#x02a7e;&#x000a0;4 on the Fagerstrom Test
of Nicotine Dependence (FTND; Heatherton <italic>et al.</italic>
<xref rid="ref29" ref-type="bibr">1991</xref>) consistent with previous research (Agrawal
<italic>et al.</italic>
<xref rid="ref1" ref-type="bibr">2009</xref>), (iv) first cigarette smoked within the
first 3&#x000a0;h after waking (to ensure cognitive results were not simply due to reversal of
withdrawal from tobacco (Jarvik <italic>et al.</italic>
<xref rid="ref36" ref-type="bibr">2000</xref>)), (v) significant respiratory, physical or
clinically diagnosed learning disorders, (vi) SR diagnosis of a psychotic disorder (or a
first degree family member with a psychotic disorder), or substance use disorder, or (vii)
SR use of illicit substance use other than cannabis more than once per week.</p></sec><sec id="sec2-4"><title>Drug administration (<xref ref-type="fig" rid="fig01">Fig. 1</xref>/<xref ref-type="table" rid="tab01">Table 1</xref>)</title><p>We compared the effects of (a) active cannabis&#x000a0;+&#x000a0;active tobacco (CAN-TOB) (b) active
cannabis&#x000a0;+&#x000a0;placebo tobacco (CAN), (c) placebo cannabis&#x000a0;+&#x000a0;active tobacco (TOB), (d) placebo
cannabis&#x000a0;+&#x000a0;placebo tobacco (no active drug) (PLACEBO). The dose of cannabis specified in
<xref ref-type="table" rid="tab01">Table 1</xref> was based on previous experimental
studies reporting robust subjective, cardiovascular, psychotomimetic and memory impairing
effects (Lawn <italic>et al.</italic>
<xref rid="ref39" ref-type="bibr">2016</xref>; Mokrysz <italic>et al.</italic>
<xref rid="ref47" ref-type="bibr">2016</xref>). This dose of tobacco reliably produces
peak plasma nicotine levels &#x0003e;20&#x000a0;ng/ml (Mendelson <italic>et al.</italic>
<xref rid="ref46" ref-type="bibr">2003</xref>, <xref rid="ref45" ref-type="bibr">2005</xref>) and is similar to a standard cannabis&#x000a0;+&#x000a0;tobacco joint (Hunault <italic>et
al.</italic>
<xref rid="ref34" ref-type="bibr">2009</xref>; Van Der Pol <italic>et al.</italic>
<xref rid="ref64" ref-type="bibr">2014</xref>). Placebo tobacco was the same dose of Very
Low Nicotine (VLN; typically referred to as denicotinized) tobacco (Magic 0; XXII Century
Group Ltd). <fig id="fig01" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Drug administration was conducted using &#x02018;joints&#x02019;, the most common method of
administering cannabis (Hindocha <italic>et al.</italic>
<xref rid="ref32" ref-type="bibr">2016</xref>). &#x02018;Study drug&#x02019; region contained a
mixture of 66.67&#x000a0;mg cannabis (active or placebo) and 311&#x000a0;mg tobacco (active or
placebo) dependent on condition (see <xref ref-type="table" rid="tab01">Table
1</xref>). The &#x02018;placebo tobacco filler&#x02019; region contained 311&#x000a0;mg of placebo tobacco
at the bottom of the joint (nearest to the mouth), which was not smoked. This filler
was added to improve compliance with the fixed inhalation procedure (see online
Supplementary Materials), as puff volume typically decreases towards the end of the
joint, probably due to rising heat (Van Der Pol <italic>et al.</italic>
<xref rid="ref64" ref-type="bibr">2014</xref>). The stop line is the point at which
participants stopped smoking the joint, separating the two regions. It was marked
1&#x000a0;cm after the &#x02018;study drug&#x02019; to ensure complete inhalation.</p></caption><graphic xlink:href="S0033291717001222_fig1"/></fig></p></sec><sec id="sec2-5"><title>Procedure</title><p>After telephone screening, eligible participants attended a baseline session involving
further screening and task training and then four experimental sessions. Each experimental
session began with pre-drug Visual Analogue Scales (VAS), physiological measures and a CO
measurement to check abstinence from smoking. Participants then listened to a passage of
prose and were required to immediately recall its content (story 1). Drug administration
took place immediately after this (see online Supplementary Materials for full details on
smoking procedure). Thirty-five minutes after drug administration, participants listened
to a second passage of prose and immediately recalled its contents (story 2). Delayed
recall of story 1 and 2 occurred approximately 55&#x000a0;min after drug administration.
Participants completed the N-back and Psychotomimetic States Inventory (PSI; Mason
<italic>et al.</italic>
<xref rid="ref44" ref-type="bibr">2008</xref>) at 21 and 45&#x000a0;min, respectively (see the
assessment flowchart online Supplementary Fig. S2). Other tasks that are not reported here
took place in the intervening time. Participants were reimbursed &#x000a3;60 for their time and
debriefed fully.</p></sec><sec id="sec2-6"><title>Assessments</title><sec id="sec2-6-1"><title>Baseline measures</title><p>Participants completed the Beck Depression Inventory (BDI; Beck <italic>et al.</italic>
<xref rid="ref3" ref-type="bibr">1996</xref>), Spielberger State-Trait Anxiety Inventory
(STAI; Spielberger <italic>et al.</italic>
<xref rid="ref61" ref-type="bibr">1970</xref>), Schizotypal Personality Questionnaire
(SPQ; Raine, <xref rid="ref54" ref-type="bibr">1991</xref>) and a detailed drug history
including questions about cannabis and tobacco co-use. CO, heart rate (HR), systolic and
diastolic blood pressure (BP) and subjective effects were measured pre- (&#x02212;10) and at 10,
30, 40 and 70&#x000a0;min&#x02019; post-drug.</p></sec><sec id="sec2-6-2"><title>Cognitive measures</title><p>The Prose Recall subtest of the Rivermead Behavioral Memory Test (Wilson <italic>et al.</italic>
<xref rid="ref66" ref-type="bibr">1991</xref>) taps episodic memory. Participants were
required to listen to a passage of prose (a 30&#x000a0;s news bulletin) and recall its contents
both immediately and after a delay. The first story (1) was heard before drug
administration, followed by immediate recall. The second story (2) was heard 35&#x000a0;min
after drug administration. Delayed recall of both was approximately 55&#x000a0;min after drug
administration. This design was chosen to dissociate drug effects on encoding from
retrieval (Fletcher &#x00026; Honey, <xref rid="ref19" ref-type="bibr">2006</xref>).
Drug effects on encoding would be evidenced by story 2 (both immediate and delayed)
being affected, but not story 1 (i.e. a drug&#x000a0;&#x000d7;&#x000a0;story interaction). If there were drug
effects on retrieval, this would be evidenced by a difference on delayed, but not
immediate, recall of story 1 (i.e. a drug&#x000a0;&#x000d7;&#x000a0;story&#x000a0;&#x000d7;&#x000a0;delay interaction). Each story
contained 21 &#x02018;idea units&#x02019; and scoring was systematic. The primary outcome is the mean
number of idea units recalled. The eight versions were counterbalanced across drug and
design.</p><p>A Spatial N-back was used to assess spatial working memory. Visual stimuli (smiley
faces) appeared in one of six different locations around a central fixation cross on the
computer screen, in a sequential order (Freeman <italic>et al.</italic>
<xref rid="ref21" ref-type="bibr">2012</xref>; Morgan <italic>et al.</italic>
<xref rid="ref49" ref-type="bibr">2014</xref>). Participants responded by pressing a
&#x02018;Yes&#x02019; or &#x02018;No&#x02019; key according to whether (a) the stimuli appeared in a pre-defined
location (zero back; attentional control), (b) whether the stimulus was in the same
position as the stimulus one before (1-back), and subsequently, (c) two before (2-back).
Four versions of the task were counterbalanced across drug and design and reaction time
and accuracy were recorded.</p></sec></sec><sec id="sec2-7"><title>Psychotomimetic effects</title><p>The Psychotomimetic States Inventory (PSI) (Mason <italic>et al.</italic>
<xref rid="ref44" ref-type="bibr">2008</xref>) was used to assess current schizotypal
symptoms. It has 48 items and is specifically designed to measure drug-induced changes in
psychotic-like symptoms. It has previously been shown to be sensitive to cannabis-induced
psychotomimetic effects and has better test-retest reliability than the Clinician
Administered Dissociative States Scale (CADSS; De Simoni <italic>et al.</italic>
<xref rid="ref12" ref-type="bibr">2013</xref>).</p></sec><sec id="sec2-8"><title>Statistical analysis</title><p>Data were analysed using IBM Statistical Package for Social Sciences (IBM SPSS version
23). Outliers more than 2.5 standard deviations (<sc>s.d.</sc>) from the sample mean were
replaced with a score falling within 2.5 <sc>s.d</sc>. Normality was explored using visual
inspection of diagnostic plots. Data for the Prose Recall, N-back and PSI was analysed
using linear mixed models, which included a random intercept for subjects and two within
subjects factors of drug: Cannabis (placebo; active) and Tobacco (placebo; active).
Additional task-specific factors of Story (1, 2) and Delay (immediate, delayed) for the
prose recall and Load (0, 1, 2) for N-back outcomes (correct responses, RT,
<italic>d</italic>&#x02032;, C). VAS scores and physiological factors (HR, BP, CO) had an
additional task-specific factor of Time (1 (predrug) <italic>v.</italic> 2, 3, 4, 5
(postdrug)). The unstructured variance-covariance structure was selected following D'Souza
<italic>et al.</italic> (<xref rid="ref13" ref-type="bibr">2012</xref>). Interactions
were explored via Bonferroni corrected <italic>post-hoc</italic> comparisons locally
within hypotheses but not across hypotheses (D'Souza <italic>et al.</italic>
<xref rid="ref13" ref-type="bibr">2012</xref>). All descriptive statistics for linear
mixed models are estimated marginal means and standard error. <italic>d</italic>&#x02032; and C
(N-back) were calculated using signal detection analysis (Snodgrass &#x00026; Corwin,
<xref rid="ref60" ref-type="bibr">1988</xref>). The loglinear approach was used to
account for perfect scores (Hautus, <xref rid="ref28" ref-type="bibr">1995</xref>;
Stanislaw &#x00026; Todorov, <xref rid="ref62" ref-type="bibr">1999</xref>). Maintenance
was calculated as 1-back minus 0-back and manipulation as 2-back minus 1 back.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3-1"><title>Demographics and drug history</title><p>A total of 24 participants (12 women), with a mean&#x000a0;&#x000b1;&#x000a0;<sc>s.d.</sc> age of 24.46&#x000a0;&#x000b1;&#x000a0;3.96
completed the study. They had minimal dependence on cannabis (SDS: 0.67&#x000a0;&#x000b1;&#x000a0;0.92 (range:
0&#x02013;3)) and tobacco (FTND: 0.33&#x000a0;&#x000b1;&#x000a0;0.64 (range: 0&#x02013;2)). Those who smoked daily
(<italic>N</italic>&#x000a0;=&#x000a0;6) reported smoking their first cigarette 5.91&#x000a0;&#x000b1;&#x000a0;3.01&#x000a0;h after
waking. Baseline questionnaire scores were: STAI trait 35.75&#x000a0;&#x000b1;&#x000a0;8.60; BDI 6.17&#x000a0;&#x000b1;&#x000a0;5.82; SPQ
19.14&#x000a0;&#x000b1;&#x000a0;10.83. Other drug use apart from alcohol was minimal (see online Supplementary
Table S1).</p></sec><sec id="sec3-2"><title>Assessments</title><p>There were no significant pre-drug differences between the four drug conditions in VAS
scores, HR, BP, CO or Short State Anxiety Inventory (SSAI; Marteau &#x00026; Bekker, <xref rid="ref43" ref-type="bibr">1992</xref>). There were no significant differences on time
taken or a number of puffs between drug conditions (online Supplementary Table S2).</p></sec><sec id="sec3-3"><title>Prose recall (<xref ref-type="fig" rid="fig02">Fig. 2</xref>)</title><p>There was a cannabis&#x000a0;&#x000d7;&#x000a0;story interaction (<italic>F</italic><sub>1,23</sub>&#x000a0;=&#x000a0;18.51,
<italic>p</italic> &#x0003c;&#x000a0;0.001) and a story&#x000a0;&#x000d7;&#x000a0;delay interaction
(<italic>F</italic><sub>1,23</sub>&#x000a0;=&#x000a0;26.60, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). There
were also main effects of cannabis (<italic>F</italic><sub>1,23</sub>&#x000a0;=&#x000a0;10.65,
<italic>p</italic>&#x000a0;=&#x000a0;0.003) and delay (<italic>F</italic><sub>1,23</sub>&#x000a0;=&#x000a0;107.58,
<italic>p</italic> &#x0003c; 0.001) but not of tobacco or story. No significant
interaction between cannabis and tobacco emerged
(<italic>F</italic><sub>1,23</sub>&#x000a0;=&#x000a0;0.812, <italic>p</italic>&#x000a0;=&#x000a0;0.317). <fig id="fig02" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>(<italic>a</italic> and <italic>b</italic>) Immediate recall (<italic>a</italic>)
and delayed recall (<italic>b</italic>) under each drug condition for both story 1
(where encoding was not intoxicated) and story 2 (where encoding was intoxicated).
Under delayed recall, for story 2, we found CAN-TOB in comparison with CAN, improves
delayed recall but this was not the case for immediate recall, therefore suggesting
effects on retrieval of information that had previously been successfully encoded.
Error bars show &#x000b1;<sc>s.e.m.</sc></p></caption><graphic xlink:href="S0033291717001222_fig2"/></fig></p><p>The cannabis&#x000a0;&#x000d7;&#x000a0;story interaction showed poorer recall following cannabis (M: 7.71,
<sc>s.e.</sc>: 0.63) for story 2 in comparison with placebo (M: 10.44, <sc>s.e.</sc>:
0.68) (<italic>p &#x0003c;</italic>&#x000a0;0.001) but not for story 1
(<italic>p</italic>&#x000a0;=&#x000a0;0.324). Under placebo cannabis, there was greater recall for story 2
(M: 10.44, <sc>s.e.</sc>: 0.68) in comparison with story 1 (M: 8.45, <sc>s.e.</sc>: 0.51)
(<italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001). By contrast, for active cannabis, there was greater
recall on story 1 (M: 8.94, <sc>s.e.</sc>: 0.62), in comparison with story 2 (M: 7.71,
<sc>s.e.</sc>: 0.63) (<italic>p</italic>&#x000a0;=&#x000a0;0.019).</p><p>To test our <italic>a priori</italic> hypothesis that tobacco compensates for the
detrimental effect of cannabis on memory we compared the difference between CAN-TOB on
immediate and delayed recall for story 2 with critical <italic>t</italic> tests (<xref ref-type="fig" rid="fig02">Fig. 2<italic>a</italic></xref>). On immediate recall, there
was no difference (<italic>t</italic><sub>23</sub>&#x000a0;=&#x000a0;1.38, <italic>p</italic>&#x000a0;=&#x000a0;0.182) but
on delayed recall, scores were significantly higher after CAN-TOB compared with CAN; the
mean difference was 1.75 idea units (<sc>s.d.</sc>: 3.87)
(<italic>t</italic><sub>23</sub>&#x000a0;=&#x000a0;2.21, <italic>p</italic>&#x000a0;=&#x000a0;0.037,
<italic>d</italic>&#x000a0;=&#x000a0;0.5) (<xref ref-type="fig" rid="fig02">Fig.
2<italic>b</italic></xref>).</p><p>The story&#x000a0;&#x000d7;&#x000a0;delay interaction showed that story 2 (M: 8.47, <sc>s.e.</sc>: 0.61) was
remembered better than story 1 (M: 7.31, <sc>s.e.</sc>: 0.61) after the delay
(<italic>p</italic>&#x000a0;=&#x000a0;0.007) but there was no difference for immediate recall
(<italic>p</italic>&#x000a0;=&#x000a0;0.360), which suggests a recency effect. The main effect of cannabis
(M: 8.32, <sc>s.e.</sc>: 0.56) clearly showed that cannabis impaired recall in comparison
with placebo (M: 9.45, <sc>s.e.</sc>: 0.54). The main effect of delay simply showed
delayed recall (M: 7.89, <sc>s.e.</sc>: 0.58) was poorer than immediate recall (M: 9.88,
<sc>s.e.</sc>: 0.48).</p></sec><sec id="sec3-4"><title>N-back</title><sec id="sec3-4-1"><title>Correct responses (<xref ref-type="fig" rid="fig03">Fig.
3<italic>a</italic></xref>, <xref ref-type="fig" rid="fig03">
<italic>b</italic>
</xref>)</title><p>There was a cannabis&#x000a0;&#x000d7;&#x000a0;load interaction (<italic>F</italic><sub>2,23</sub>&#x000a0;=&#x000a0;4.82,
<italic>p</italic>&#x000a0;=&#x000a0;0.018), which showed that cannabis impaired the 1- and 2-back but
not the zero-back (<xref ref-type="fig" rid="fig03">Fig. 3<italic>a</italic></xref>;
also online Supplementary Table S3). A main effect of cannabis
(<italic>F</italic><sub>1,23</sub>&#x000a0;=&#x000a0;15.93, <italic>p</italic>&#x000a0;=&#x000a0;0.001), reflected
better performance on placebo than cannabis and a main effect of tobacco
(<italic>F</italic><sub>1,23</sub>&#x000a0;=&#x000a0;4.88, <italic>p</italic>&#x000a0;=&#x000a0;0.037) reflected
better performance on active tobacco (M: 43.77, <sc>s.e.</sc>: 0.55) than placebo (M:
42.58, <sc>s.e.</sc>: 0.56) across all load conditions (<xref ref-type="fig" rid="fig03">Fig. 3<italic>b</italic></xref>). A main effect of load
(<italic>F</italic><sub>2,23</sub>&#x000a0;=&#x000a0;43.42, <italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001) reflected
better performance on 0-back than 1- and 2-back, respectively. No significant
interaction between cannabis and tobacco emerged. The critical a <italic>priori
t</italic> test between CAN-TOB and CAN on N-back correct responses across all loads was
not significant (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.5). <fig id="fig03" orientation="portrait" position="float"><label>Fig. 3.</label><caption><p>(<italic>a&#x02013;d</italic>) Number of correct responses (<italic>a</italic> &#x00026;
<italic>b</italic>) and <italic>d</italic>&#x02032; (<italic>c</italic> &#x00026;
<italic>d</italic>) for cannabis <italic>v.</italic> placebo (<italic>a</italic>
&#x00026; <italic>c</italic>) and tobacco <italic>v.</italic> placebo
(<italic>b</italic> &#x00026; <italic>d</italic>) for the N-back. Error bars show
&#x000b1;<sc>s.e.m.</sc></p></caption><graphic xlink:href="S0033291717001222_fig3"/></fig></p></sec><sec id="sec3-4-2"><title>Signal detection analysis (<xref ref-type="fig" rid="fig03">Fig.
3<italic>c</italic></xref>, <xref ref-type="fig" rid="fig03">
<italic>d</italic>
</xref>)</title><p><italic>d</italic>&#x02032;: there was a main effect of cannabis
(<italic>F</italic><sub>1,23</sub>&#x000a0;=&#x000a0;14.48, <italic>p</italic> &#x0003c; 0.001) where it
reduced discriminability in comparison with placebo (<xref ref-type="fig" rid="fig03">Fig. 3<italic>c</italic></xref>), a main effect of tobacco
(<italic>F</italic><sub>1,23</sub>&#x000a0;=&#x000a0;8.25, <italic>p</italic>&#x000a0;=&#x000a0;0.009) where tobacco
increased discriminability in comparison with placebo (<xref ref-type="fig" rid="fig03">Fig. 3<italic>d</italic></xref>) and a main effect of load,
(<italic>F</italic><sub>2,23</sub>&#x000a0;=&#x000a0;28.33, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). The
highest discriminability was for the 0-back, followed by the 1-back, followed by the
2-back and there were no significant interactions. The critical apriori
<italic>t</italic> test between CAN-TOB and CAN on <italic>d</italic>&#x02032; averaging over
all loads showed a trend towards higher scores with CAN-TOB in comparison with CAN
(<italic>t</italic><sub>23</sub>&#x000a0;=&#x000a0;2.00, <italic>p</italic>&#x000a0;=&#x000a0;0.059,
<italic>d</italic>&#x000a0;=&#x000a0;0.47).</p><p><italic>Criterion</italic> (<italic>C</italic>): there was a main effect of load
(<italic>F</italic><sub>2,23</sub>&#x000a0;=&#x000a0;245.90, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001)
whereby the criterion was higher for the 0-back (M: 0.50, <sc>s.e.</sc>: 0.02), followed
by the 1-back (M: &#x02212;0.04, <sc>s.e.</sc>: 0.02) and 2-back (M: &#x02212;0.06, <sc>s.e.</sc>:
0.03).</p></sec><sec id="sec3-4-3"><title>Reaction time</title><p>There was a cannabis&#x000a0;&#x000d7;&#x000a0;load interaction (<italic>F</italic><sub>2,23</sub>&#x000a0;=&#x000a0;8.82,
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), which showed that cannabis impaired the 2-back in
comparison with placebo (<italic>p</italic>&#x000a0;=&#x000a0;0.005) but not the 1-back
(<italic>p</italic>&#x000a0;=&#x000a0;0.214) or the 0 back (<italic>p</italic>&#x000a0;=&#x000a0;0.979). There was a
main effect of load (<italic>F</italic><sub>2,23</sub>&#x000a0;=&#x000a0;68.90,
<italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001), which showed increasing RT across load. There were
no main effects or interactions with tobacco.</p></sec><sec id="sec3-4-4"><title>Manipulation and maintenance</title><p>A main effect of cannabis on manipulation (<italic>F</italic><sub>1,23</sub>&#x000a0;=&#x000a0;5.86,
<italic>p</italic>&#x000a0;=&#x000a0;0.024) showed cannabis impaired manipulation (M: &#x02212;5.67,
<sc>s.e.</sc>: 1.04) in comparison with placebo (M: &#x02212;3.27, <sc>s.e.</sc>: 0.77); there
were no other effects or interactions. No main effects or interactions emerged for
maintenance.</p></sec></sec><sec id="sec3-5"><title>Psychotomimetic states inventory</title><p>A main effect of cannabis (<italic>F</italic><sub>1,33</sub>&#x000a0;=&#x000a0;33.01,
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) showed cannabis (M: 32.04, <sc>s.e.</sc>: 3.53)
markedly increased PSI scores in comparison with placebo (M: 13.85, <sc>s.e.</sc>: 1.76);
there were no other effects or interactions. The same pattern of results emerged when
including PSI subscale as an additional factor. Schizotypy has previously been found to
predict acute psychotomimetic response to cannabis; therefore, we added SPQ score as an
additional covariate. This did not reveal any interactions between SPQ score and drug
effect on the PSI.</p></sec><sec id="sec3-6"><title>Physiological measures</title><sec id="sec3-6-1"><title>Carbon monoxide (<xref ref-type="fig" rid="fig04">Fig. 4<italic>a</italic></xref>)</title><p>There was a main effect of cannabis (<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;4.32,
<italic>p</italic>&#x000a0;=&#x000a0;0.039), which showed that under active cannabis, participants had
a lower CO than under placebo cannabis. There was also a main effect of time
(<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;415.49, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). <fig id="fig04" orientation="portrait" position="float"><label>Fig. 4.</label><caption><p>(<italic>a&#x02013;f</italic>) carbon monoxide (CO), cardiovascular (heart rate (HR),
systolic and diastolic blood pressure (mmHg)) and self-reported effects for stoned
and dizzy for all time points before (T1) and after (T2&#x02013;T5) each drug
administration. Error bars show &#x000b1;<sc>s.e.m.</sc></p></caption><graphic xlink:href="S0033291717001222_fig4"/></fig></p></sec><sec id="sec3-6-2"><title>Heart rate (<xref ref-type="fig" rid="fig04">Fig. 4<italic>b</italic></xref>)</title><p>A cannabis&#x000a0;&#x000d7;&#x000a0;time interaction (<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;62.88,
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) revealed a significant increase on active cannabis,
compared with placebo cannabis, post-drug administration (MDiff: 22.71, <sc>s.e.</sc>:
2.22, <italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001), but no difference pre-drug. It also revealed
an increase between pre-and post-drug for active cannabis (MDiff: 27.31, <sc>s.e.</sc>:
2.20, <italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001), but not for placebo cannabis. A tobacco&#x000a0;&#x000d7;&#x000a0;time
interaction (<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;4.49, <italic>p</italic>&#x000a0;=&#x000a0;0.036)
revealed a significant increase between tobacco and placebo, post-drug (MDiff: 6.88,
<sc>s.e.</sc>: 2.20; <italic>p</italic>&#x000a0;=&#x000a0;0.002). There was no difference between
tobacco and placebo pre-drug. Under both placebo and active tobacco, there was an
increase in HR from pre- to post-drug (placebo tobacco MDiff: 11.53, <sc>s.e.</sc>:
2.20; <italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001, active tobacco MDiff: 18.18, <sc>s.e.</sc>:
2.20, <italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001). There were main effects of cannabis
(<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;42.73, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001),
tobacco (<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;5.125, <italic>p</italic>&#x000a0;=&#x000a0;0.025) and
time (<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;89.53,
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001).</p></sec><sec id="sec3-6-3"><title>Blood pressure (<xref ref-type="fig" rid="fig04">Fig. 4<italic>c</italic></xref>,
<xref ref-type="fig" rid="fig04">
<italic>d</italic>
</xref>)</title><p>For diastolic blood pressure, there was a cannabis&#x000a0;&#x000d7;&#x000a0;tobacco&#x000a0;&#x000d7;&#x000a0;time interaction
(<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;5.56, <italic>p</italic>&#x000a0;=&#x000a0;0.02). All drugs
conditions, with the exception of PLACEBO, increased diastolic BP from pre- to post-
drug. At the post-drug time point, this manifested in greater diastolic BP under TOB
(MDiff: 6.33, <sc>s.e.</sc>: 1.61, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and CAN (MDiff:
6.22, <sc>s.e.</sc>: 1.61, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) than CAN-TOB (MDiff: 1.26,
<sc>s.e.</sc>: 1.61, <italic>p</italic>&#x000a0;=&#x000a0;0.44). There was also a cannabis&#x000a0;&#x000d7;&#x000a0;tobacco
interaction, which was explained/subsumed by the above three-way interaction
(<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;5.70, <italic>p</italic>&#x000a0;=&#x000a0;0.2). Finally, there
was a cannabis&#x000a0;&#x000d7;&#x000a0;time interaction (<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;4.64,
<italic>p</italic>&#x000a0;=&#x000a0;0.03), which revealed a significant that active cannabis increased
diastolic blood pressure, pre- to post-drug (MDiff: 4.51, <sc>s.e.</sc>: 1.13;
<italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001), but not under placebo cannabis. There was also a
main effect of time (<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;11.91,
<italic>p</italic>&#x000a0;=&#x000a0;0.001). There were no other main effects or interaction. For
systolic blood pressure, a cannabis&#x000a0;&#x000d7;&#x000a0;tobacco interaction
(<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;4.65, <italic>p</italic>&#x000a0;=&#x000a0;0.03) emerged however
pairwise comparisons revealed no significant differences between cannabis and placebo or
between pre- and post-drug timepoints.</p></sec></sec><sec id="sec3-7"><title>Self-ratings</title><sec id="sec3-7-1"><title>Stoned (<xref ref-type="fig" rid="fig04">Fig. 4<italic>e</italic></xref>)</title><p>There was a cannabis&#x000a0;&#x000d7;&#x000a0;time interaction (<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;84.59,
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), which revealed a significant increase pre- to
post-drug for active cannabis (MDiff: 4.95, <sc>s.e.</sc>: 0.31;
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and for placebo cannabis to a lesser extent (MDiff:
0.91, <sc>s.e.</sc>: 0.31; <italic>p</italic>&#x000a0;=&#x000a0;0.004). There was no difference between
placebo and active cannabis pre-drug, however, there was a significant difference post-
drug (MDiff: 4.02, <sc>s.e.</sc>: 0.31; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). There was
also a main effect of cannabis (<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;82.85,
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and a main effect of time
(<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;178.25, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001).
There were no main effects or interactions with tobacco.</p></sec><sec id="sec3-7-2"><title>Dizzy (<xref ref-type="fig" rid="fig04">Fig. 4<italic>f</italic></xref>)</title><p>There was a cannabis&#x000a0;&#x000d7;&#x000a0;time interaction (<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;17.07,
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), which revealed a significant increase pre- to
post-drug for active cannabis (MDiff: 2.41, <sc>s.e.</sc>: 0.27;
<italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001) and for placebo cannabis to a lesser extent (MDiff:
0.83, <sc>s.e.</sc>: 0.27; <italic>p</italic>&#x000a0;=&#x000a0;0.002). Pre-drug, there was no
difference between active and placebo cannabis (<italic>p</italic>&#x000a0;=&#x000a0;0.817) however
active cannabis increased &#x02018;dizzy&#x02019; ratings post-drug (MDiff: 1.51, <sc>s.e.</sc>: 0.27,
<italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001). There were significant main effects of cannabis
(<italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;17.46, <italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001), and
time (<italic>F</italic><sub>1,23</sub>&#x000a0;=&#x000a0;29.15, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). No
tobacco&#x000a0;&#x000d7;&#x000a0;time or cannabis&#x000a0;&#x000d7;&#x000a0;tobacco&#x000a0;&#x000d7;&#x000a0;time interactions emerged.</p></sec></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>In the first study to investigate the acute interaction between cannabis and tobacco using
a controlled randomised crossover design with an ecological method of drug administration,
we found that cannabis impairs episodic memory. We found preliminary evidence to support our
hypothesis that tobacco would offset the effects of cannabis on verbal recall. However, this
finding emerged for delayed but not immediate recall, and was not supported by linear mixed
model analysis, so should be treated with caution until replicated. When active tobacco is
combined with active cannabis the impairment in delayed recall is slightly attenuated in
comparison with cannabis alone. In regards to WM, we saw opposite independent effects
whereby cannabis was detrimental to WM, and tobacco improved working memory performance. We
also found that tobacco had no effect on cannabis-induced psychotic-like experiences. In
regards to physiological effects, all drug conditions apart from the placebo increased
diastolic BP post-drug. Diastolic BP was lower under mixed cannabis and tobacco than either
cannabis alone or tobacco alone. The biological mechanisms of this effect are uncertain, but
warrant further investigation, as mixed tobacco and cannabis is the primary route of
self-administration. Both cannabis and tobacco had independent effects on HR, with cannabis
producing greater increases in HR than tobacco. Tobacco did not influence ratings of
&#x02018;stoned&#x02019; or &#x02018;dizzy&#x02019;, which are classic cannabis-induced effects. Taken together, we found
minimal evidence for interactive effects of cannabis and tobacco in a controlled 2&#x000a0;&#x000d7;&#x000a0;2
design with an ecological method of drug administration. However, our results tentatively
suggest that the common practise of adding tobacco to cannabis in joints (Hindocha
<italic>et al.</italic>
<xref rid="ref32" ref-type="bibr">2016</xref>) may reduce cognitive impairment from
cannabis, but does not influence users&#x02019; psychotic-like experiences or subjective experience
of the drug.</p><p>Previous research has shown that cannabis acutely induces robust cognitive deficits in
working and episodic memory (Curran <italic>et al.</italic>
<xref rid="ref9" ref-type="bibr">2002</xref>; D'Souza <italic>et al.</italic>
<xref rid="ref14" ref-type="bibr">2004</xref>; Morrison <italic>et al.</italic>
<xref rid="ref50" ref-type="bibr">2009</xref>; Bossong <italic>et al.</italic>
<xref rid="ref4" ref-type="bibr">2012</xref>). Tobacco has been shown to have the opposite
effect on the same cognitive constructs but with much smaller effect sizes (Heishman
<italic>et al.</italic>
<xref rid="ref30" ref-type="bibr">2010</xref>) and both drugs act on receptors that densely
populate the hippocampus. The <italic>a priori</italic> comparison on a prose recall task
show, although there was no cannabis&#x000a0;&#x000d7;&#x000a0;tobacco interaction in the linear mixed model
analysis, participants performed significantly better after cannabis and tobacco combined
than cannabis alone for delayed recall (mean difference: 1.75 idea units) but not for
immediate recall. These findings are similar to Englund <italic>et al.</italic> (<xref rid="ref16" ref-type="bibr">2013</xref>) who found that THC-induced impairments in delayed
but not immediate recall were attenuated by pre-treatment of CBD (Englund <italic>et al.</italic>
<xref rid="ref16" ref-type="bibr">2013</xref>). Together, the prose recall and N-back
results suggest that tobacco/nicotine increased attentional resources that may be involved
in trying to recall information that had previously been encoding correctly. The delayed
recall task is more difficult and requires greater attentional resources than the immediate
recall task, and these results are in line with the general improvement effect found on the
N-back. These results are also consistent with a recent study of chronic cannabis use, which
found a cannabis&#x000a0;&#x000d7;&#x000a0;tobacco interaction for delayed recall. However, this effect was only
evident among those who consistently smoked cigarettes (&#x0003e;100 per year) in comparison
with those who sporadically smoked cigarettes (&#x0003c;100 per year) (Schuster <italic>et
al.</italic>
<xref rid="ref57" ref-type="bibr">2015</xref>). However, this study did not use a controlled
design, used a relatively arbitrary cut-off for cigarettes and could not investigate adding
tobacco to cannabis in the same product.</p><p>In regards to WM, we found the detrimental effect of cannabis (in comparison with placebo)
on the N-back were load-dependent i.e. impairment increased with load, and was selective to
manipulation (not maintenance). By contrast, facilitative effects of tobacco on correct
responses and discriminability were load-independent, and did not influence manipulation or
maintenance, perhaps suggesting that tobacco effects are purely on attention. This is
consistent with previous function magnetic resonance imaging (fMRI) research showing
nicotine altered activity in a neural network associated with task monitoring and attention
(Kumari <italic>et al.</italic>
<xref rid="ref38" ref-type="bibr">2003</xref>). Our results are consistent with a recent
naturalistic study (Schuster <italic>et al.</italic>
<xref rid="ref58" ref-type="bibr">2016</xref>), which used a 40-s WM task on mobile phones
and found WM was impaired by cannabis, improved by tobacco, and when used simultaneously,
participants showed no impairment. Moreover, both Schuster <italic>et al.</italic> (<xref rid="ref58" ref-type="bibr">2016</xref>) and the present study did not find evidence for a
cannabis&#x000a0;&#x000d7;&#x000a0;tobacco interaction for WM performance. In the present study <italic>a
priori</italic> comparisons between cannabis&#x000a0;+&#x000a0;tobacco and cannabis alone were only
approaching significance for <italic>d</italic>&#x02032;. Our findings complement those of Schuster
<italic>et al.</italic> (<xref rid="ref58" ref-type="bibr">2016</xref>) and provide
impetus for further investigation into the interactive effects of cannabis and tobacco on
cognition. This study may also provide some mechanistic insights into memory and why both
substances may be co-administered however, it would be essential to replicate this finding
in another controlled study. One potential consequence of nicotinic attenuation of the
effects of THC on memory may be that it feeds into continued drug taking as certain acute
adverse effects are diminished. These results may have relevance to dual diagnosis
populations, for whom rates of both cigarette and cannabis (and tobacco), use are high,
presenting an important line of future research.</p><p>Tobacco had no effect on feeling &#x02018;stoned&#x02019; or &#x02018;dizzy&#x02019; despite this strongly-held belief that
adding tobacco to cannabis increases positive subjective effects (Amos <italic>et al.</italic>
<xref rid="ref2" ref-type="bibr">2004</xref>). Although tobacco potentially offset some of
the impairing effect of cannabis on memory, this occurred in absence of any positive
subjective effects. This is in contrast to previous human experimental research, which found
that nicotine patch pre-treatment increased reports of feeling stimulated and an
amphetamine-like feelings scale (Penetar <italic>et al.</italic>
<xref rid="ref51" ref-type="bibr">2005</xref>). However, we found a cannabis&#x000a0;&#x000d7;&#x000a0;tobacco
interaction on diastolic BP, and independent effects of cannabis and tobacco on heart rate,
which suggest that combining the two, increases the cardiovascular risk of smoking cannabis
(for diastolic BP, the combined was lower than cannabis alone and tobacco alone, however
this does not negate the increase in diastolic BP). There is a clear public health
implication here, suggesting that smoking cannabis with tobacco does not improve the
subjective effects of cannabis, and makes it more harmful to one's physical health.</p><p>In relation to the PSI results, we found no modification of PSI scores by either tobacco
alone or in combination with cannabis. This corresponds to research that finds nicotine also
fails to attenuate ketamine-induced psychotic-like experiences and cognitive deficits
(D'Souza <italic>et al.</italic>
<xref rid="ref13" ref-type="bibr">2012</xref>). In recent epidemiological studies, tobacco
and cannabis have been shown to independently predict the rate of psychotic-like experiences
(Van Gastel <italic>et al.</italic>
<xref rid="ref65" ref-type="bibr">2013</xref>; Gage <italic>et al.</italic>
<xref rid="ref22" ref-type="bibr">2014</xref>). However, the relationship between cannabis,
tobacco, and psychosis is complicated given tobacco and cannabis are so strongly correlated.
These findings do not negate a possible long-term effect of tobacco on psychosis. However,
they suggest that such an association is less biologically plausible than for cannabis, as
evidenced by acute drug effects.</p><sec id="sec4-1"><title>Strengths and limitations</title><p>Strengths of this study include a large sample size (informed by an <italic>a
priori</italic> power calculation), its double-blind, randomized,
double-placebo-controlled, crossover design, and use of well-validated tasks. Furthermore,
we selected participants with minimal dependence on tobacco (and cannabis), which suggests
that nicotinic facilitation was not purely due to the reversal of withdrawal effects. We
used the PSI, which has better test-retest reliability than other scales designed to tap
psychotic like effects (De Simoni <italic>et al.</italic>
<xref rid="ref12" ref-type="bibr">2013</xref>). Pharmacokinetics (PK)/pharmacodynamics(PD)
were not measured so we are unable to comment on temporal changes that occur. For example,
previous research has shown that nicotine increases the length of the cannabis effect in
some participants (Penetar <italic>et al.</italic>
<xref rid="ref51" ref-type="bibr">2005</xref>). Furthermore, nicotine effects reduce
quickly after administration (Mendelson <italic>et al.</italic>
<xref rid="ref46" ref-type="bibr">2003</xref>, <xref rid="ref45" ref-type="bibr">2005</xref>) in comparison with the cannabis effect and we were not able to conduct
multiple dosing studies or ideally, an intravenous study (D'Souza <italic>et al.</italic>
<xref rid="ref13" ref-type="bibr">2012</xref>) however the short-testing window was
designed to capture nicotine's effects. Finally, given the novelty of the research, with
multiple statistical comparisons study of cannabis and tobacco, we would suggest that
these findings be treated with caution until replicated.</p></sec></sec><sec sec-type="conclusion" id="sec5"><title>Conclusions</title><p>In conclusion, this study found that cannabis impaired working and episodic memory. We
found preliminary evidence that tobacco co-administration may offset the effects of cannabis
on episodic memory. We characterised the acute subjective and cardiovascular effects of
cannabis and tobacco administered together through a shared route of administration (i.e.
joints) and found that these effects were similar to cannabis alone. There was no effect of
tobacco on cannabis induced psychotomimetic effects.</p></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This research was funded by a UK Medical Research Council Studentship awarded to the first
author. Funders had no role in the study design, analysis or interpretation of the data, or
in the writing of the report. We would like to acknowledge 21 Century Ltd for providing the
denicotinized tobacco. We would also like to acknowledge the helpful comments of three
anonymous reviewers.</p></ack><sec sec-type="supplementary-material" id="sec6"><title>Supplementary material</title><supplementary-material content-type="local-data" id="S0033291717001222sup001"><p>For supplementary material accompanying this paper visit http://dx.doi.org/10.1017/S0033291717001222.</p><media xlink:href="S0033291717001222sup001.docx" mimetype="application" mime-subtype="msword" orientation="portrait" id="d35e1781" position="anchor"><caption><p>click here to view supplementary material</p></caption></media></supplementary-material></sec><notes notes-type="other" id="nts2"><title>Declaration of Interest</title><p>None.</p></notes><ref-list id="reflist1"><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><name><surname>Agrawal</surname><given-names>A</given-names></name>, <name><surname>Lynskey</surname><given-names>MT</given-names></name>, <name><surname>Madden</surname><given-names>PA</given-names></name>, <name><surname>Pergadia</surname><given-names>ML</given-names></name>, <name><surname>Bucholz</surname><given-names>KK</given-names></name>, <name><surname>Heath</surname><given-names>AC</given-names></name> (<year>2009</year>). <article-title>Simultaneous cannabis and tobacco use and
cannabis-related outcomes in young women</article-title>. <source>Drug and Alcohol
Dependence</source>
<volume>101</volume>, <fpage>8</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">19081202</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><name><surname>Amos</surname><given-names>A</given-names></name>, <name><surname>Wiltshire</surname><given-names>S</given-names></name>, <name><surname>Bostock</surname><given-names>Y</given-names></name>, <name><surname>Haw</surname><given-names>S</given-names></name>, <name><surname>Mcneill</surname><given-names>A</given-names></name> (<year>2004</year>). <article-title>&#x02018;You can't go without a fag&#x02026; you need it for
your hash&#x02019; &#x02013; a qualitative exploration of smoking, cannabis and young
people</article-title>. <source>Addiction</source>
<volume>99</volume>, <fpage>77</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">14678065</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><name><surname>Beck</surname><given-names>AT</given-names></name>, <name><surname>Steer</surname><given-names>RA</given-names></name>, <name><surname>Ball</surname><given-names>R</given-names></name>, <name><surname>Ranieri</surname><given-names>WF</given-names></name> (<year>1996</year>). <article-title>Comparison of Beck Depression Inventories-IA
and-II in psychiatric outpatients</article-title>. <source>Journal of Personality
Assessment</source>
<volume>67</volume>, <fpage>588</fpage>&#x02013;<lpage>597</lpage>.<pub-id pub-id-type="pmid">8991972</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><name><surname>Bossong</surname><given-names>MG</given-names></name>, <name><surname>Jansma</surname><given-names>JM</given-names></name>, <name><surname>Van Hell</surname><given-names>HH</given-names></name>, <name><surname>Jager</surname><given-names>G</given-names></name>, <name><surname>Oudman</surname><given-names>E</given-names></name>, <name><surname>Saliasi</surname><given-names>E</given-names></name>, <name><surname>Kahn</surname><given-names>RS</given-names></name>, <name><surname>Ramsey</surname><given-names>NF</given-names></name> (<year>2012</year>). <article-title>Effects of
<italic>&#x003b4;</italic>9-tetrahydrocannabinol on human working memory
function</article-title>. <source>Biological Psychiatry</source>
<volume>71</volume>, <fpage>693</fpage>&#x02013;<lpage>699</lpage>.<pub-id pub-id-type="pmid">22341370</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><name><surname>Broyd</surname><given-names>SJ</given-names></name>, <name><surname>Van Hell</surname><given-names>HH</given-names></name>, <name><surname>Beale</surname><given-names>C</given-names></name>, <name><surname>Yucel</surname><given-names>M</given-names></name>, <name><surname>Solowij</surname><given-names>N</given-names></name> (<year>2016</year>). <article-title>Acute and chronic effects of cannabinoids on
human cognition-a systematic review</article-title>. <source>Biol Psychiatry</source>
<volume>79</volume>, <fpage>557</fpage>&#x02013;<lpage>567</lpage>.<pub-id pub-id-type="pmid">26858214</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>C</given-names></name>, <name><surname>Kodas</surname><given-names>E</given-names></name>, <name><surname>Griebel</surname><given-names>G</given-names></name> (<year>2005</year>). <article-title>CB 1 receptor antagonists for the treatment of
nicotine addiction</article-title>. <source>Pharmacology Biochemistry and Behavior</source>
<volume>81</volume>, <fpage>387</fpage>&#x02013;<lpage>395</lpage>.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><name><surname>Cooper</surname><given-names>ZD</given-names></name>, <name><surname>Haney</surname><given-names>M</given-names></name> (<year>2009</year>). <article-title>Comparison of subjective, pharmacokinetic, and
physiological effects of marijuana smoked as joints and blunts</article-title>.
<source>Drug and Alcohol Dependence</source>
<volume>103</volume>, <fpage>107</fpage>&#x02013;<lpage>113</lpage>.<pub-id pub-id-type="pmid">19443132</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><name><surname>Crane</surname><given-names>NA</given-names></name>, <name><surname>Schuster</surname><given-names>RM</given-names></name>, <name><surname>Fusar-Poli</surname><given-names>P</given-names></name>, <name><surname>Gonzalez</surname><given-names>R</given-names></name> (<year>2013</year>). <article-title>Effects of cannabis on neurocognitive
functioning: recent advances, neurodevelopmental influences, and sex
differences</article-title>. <source>Neuropsychology Review</source>
<volume>23</volume>, <fpage>117</fpage>&#x02013;<lpage>137</lpage>.<pub-id pub-id-type="pmid">23129391</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><name><surname>Curran</surname><given-names>HV</given-names></name>, <name><surname>Brignell</surname><given-names>C</given-names></name>, <name><surname>Fletcher</surname><given-names>PC</given-names></name>, <name><surname>Middleton</surname><given-names>P</given-names></name>, <name><surname>Henry</surname><given-names>J</given-names></name> (<year>2002</year>). <article-title>Cognitive and subjective dose-response effects
of acute oral D9-tetrahydrocannabinol (THC) in infrequent cannabis
users</article-title>. <source>Psychopharmacology <italic>(</italic>Berl<italic>)</italic></source>
<volume>164</volume>, <fpage>61</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">12373420</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><name><surname>Curran</surname><given-names>HV</given-names></name>, <name><surname>Freeman</surname><given-names>TP</given-names></name>, <name><surname>Mokrysz</surname><given-names>C</given-names></name>, <name><surname>Lewis</surname><given-names>DA</given-names></name>, <name><surname>Morgan</surname><given-names>CJ</given-names></name>, <name><surname>Parsons</surname><given-names>LH</given-names></name> (<year>2016</year>). <article-title>Keep off the grass? Cannabis, cognition and
addiction</article-title>. <source>Nature Reviews Neuroscience</source>
<volume>17</volume>, <fpage>293</fpage>&#x02013;<lpage>306</lpage>.<pub-id pub-id-type="pmid">27052382</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><name><surname>De Leon</surname><given-names>J</given-names></name>, <name><surname>Diaz</surname><given-names>FJ</given-names></name> (<year>2005</year>). <article-title>A meta-analysis of worldwide studies
demonstrates an association between schizophrenia and tobacco smoking
behaviors</article-title>. <source>Schizophrenia Research</source>
<volume>76</volume>, <fpage>135</fpage>&#x02013;<lpage>157</lpage>.<pub-id pub-id-type="pmid">15949648</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><name><surname>De Simoni</surname><given-names>S</given-names></name>, <name><surname>Schwarz</surname><given-names>AJ</given-names></name>, <name><surname>O'daly</surname><given-names>OG</given-names></name>, <name><surname>Marquand</surname><given-names>AF</given-names></name>, <name><surname>Brittain</surname><given-names>C</given-names></name>, <name><surname>Gonzales</surname><given-names>C</given-names></name>, <name><surname>Stephenson</surname><given-names>S</given-names></name>, <name><surname>Williams</surname><given-names>SC</given-names></name>, <name><surname>Mehta</surname><given-names>MA</given-names></name> (<year>2013</year>). <article-title>Test&#x02013;retest reliability of the BOLD
pharmacological MRI response to ketamine in healthy volunteers</article-title>.
<source>NeuroImage</source>
<volume>64</volume>, <fpage>75</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">23009959</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><name><surname>D'souza</surname><given-names>DC</given-names></name>, <name><surname>Ahn</surname><given-names>K</given-names></name>, <name><surname>Bhakta</surname><given-names>S</given-names></name>, <name><surname>Elander</surname><given-names>J</given-names></name>, <name><surname>Singh</surname><given-names>N</given-names></name>, <name><surname>Nadim</surname><given-names>H</given-names></name>, <name><surname>Jatlow</surname><given-names>P</given-names></name>, <name><surname>Suckow</surname><given-names>RF</given-names></name>, <name><surname>Pittman</surname><given-names>B</given-names></name>, <name><surname>Ranganathan</surname><given-names>M</given-names></name> (<year>2012</year>). <article-title>Nicotine fails to attenuate ketamine-induced
cognitive deficits and negative and positive symptoms in humans: implications for
schizophrenia</article-title>. <source>Biological Psychiatry</source>
<volume>72</volume>, <fpage>785</fpage>&#x02013;<lpage>794</lpage>.<pub-id pub-id-type="pmid">22717030</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><name><surname>D'souza</surname><given-names>DC</given-names></name>, <name><surname>Perry</surname><given-names>E</given-names></name>, <name><surname>Macdougall</surname><given-names>L</given-names></name>, <name><surname>Ammerman</surname><given-names>Y</given-names></name>, <name><surname>Cooper</surname><given-names>T</given-names></name>, <name><surname>Wu</surname><given-names>Y-t</given-names></name>, <name><surname>Braley</surname><given-names>G</given-names></name>, <name><surname>Gueorguieva</surname><given-names>R</given-names></name>, <name><surname>Krystal</surname><given-names>JH</given-names></name> (<year>2004</year>). <article-title>The psychotomimetic effects of intravenous
delta-9-tetrahydrocannabinol in healthy individuals: implications for
psychosis</article-title>. <source>Neuropsychopharmacology</source>
<volume>29</volume>, <fpage>1558</fpage>&#x02013;<lpage>1572</lpage>.<pub-id pub-id-type="pmid">15173844</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><name><surname>D'souza</surname><given-names>DC</given-names></name>, <name><surname>Ranganathan</surname><given-names>M</given-names></name>, <name><surname>Braley</surname><given-names>G</given-names></name>, <name><surname>Gueorguieva</surname><given-names>R</given-names></name>, <name><surname>Zimolo</surname><given-names>Z</given-names></name>, <name><surname>Cooper</surname><given-names>T</given-names></name>, <name><surname>Perry</surname><given-names>E</given-names></name>, <name><surname>Krystal</surname><given-names>J</given-names></name> (<year>2008</year>). <article-title>Blunted psychotomimetic and amnestic effects
of delta-9-tetrahydrocannabinol in frequent users of cannabis</article-title>.
<source>Neuropsychopharmacology</source>
<volume>33</volume>, <fpage>2505</fpage>&#x02013;<lpage>2516</lpage>.<pub-id pub-id-type="pmid">18185500</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><name><surname>Englund</surname><given-names>A</given-names></name>, <name><surname>Morrison</surname><given-names>PD</given-names></name>, <name><surname>Nottage</surname><given-names>J</given-names></name>, <name><surname>Hague</surname><given-names>D</given-names></name>, <name><surname>Kane</surname><given-names>F</given-names></name>, <name><surname>Bonaccorso</surname><given-names>S</given-names></name>, <name><surname>Stone</surname><given-names>JM</given-names></name>, <name><surname>Reichenberg</surname><given-names>A</given-names></name>, <name><surname>Brenneisen</surname><given-names>R</given-names></name>, <name><surname>Holt</surname><given-names>D</given-names></name> (<year>2013</year>). <article-title>Cannabidiol inhibits THC-elicited paranoid
symptoms and hippocampal-dependent memory impairment</article-title>. <source>Journal of
Psychopharmacology</source>
<volume>27</volume>, <fpage>19</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">23042808</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><name><surname>Faul</surname><given-names>F</given-names></name>, <name><surname>Erdfelder</surname><given-names>E</given-names></name>, <name><surname>Lang</surname><given-names>AG</given-names></name>, <name><surname>Buchner</surname><given-names>A</given-names></name> (<year>2007</year>). <article-title>G*Power 3: a flexible statistical power
analysis program for the social, behavioral, and biomedical sciences</article-title>.
<source>Behavior Research Methods</source>
<volume>39</volume>, <fpage>175</fpage>&#x02013;<lpage>191</lpage>.<pub-id pub-id-type="pmid">17695343</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><name><surname>Fernandez-Ruiz</surname><given-names>J</given-names></name>, <name><surname>Hernandez</surname><given-names>M</given-names></name>, <name><surname>Ramos</surname><given-names>JA</given-names></name> (<year>2010</year>). <article-title>Cannabinoid-dopamine interaction in the
pathophysiology and treatment of CNS disorders</article-title>. <source>CNS Neuroscience
&#x00026; Therapeutics</source>
<volume>16</volume>, <fpage>e72</fpage>&#x02013;<lpage>e91</lpage>.<pub-id pub-id-type="pmid">20406253</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><name><surname>Fletcher</surname><given-names>PC</given-names></name>, <name><surname>Honey</surname><given-names>GD</given-names></name> (<year>2006</year>). <article-title>Schizophrenia, ketamine and cannabis: evidence
of overlapping memory deficits</article-title>. <source>Trends in Cognitive Sciences</source>
<volume>10</volume>, <fpage>167</fpage>&#x02013;<lpage>174</lpage>.<pub-id pub-id-type="pmid">16531099</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><name><surname>Forget</surname><given-names>B</given-names></name>, <name><surname>Hamon</surname><given-names>M</given-names></name>, <name><surname>Thi&#x000e9;bot</surname><given-names>M-H</given-names></name> (<year>2005</year>). <article-title>Cannabinoid CB1 receptors are involved in
motivational effects of nicotine in rats</article-title>. <source>Psychopharmacology</source>
<volume>181</volume>, <fpage>722</fpage>&#x02013;<lpage>734</lpage>.<pub-id pub-id-type="pmid">15986197</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><name><surname>Freeman</surname><given-names>TP</given-names></name>, <name><surname>Morgan</surname><given-names>CJ</given-names></name>, <name><surname>Vaughn-Jones</surname><given-names>J</given-names></name>, <name><surname>Hussain</surname><given-names>N</given-names></name>, <name><surname>Karimi</surname><given-names>K</given-names></name>, <name><surname>Curran</surname><given-names>HV</given-names></name> (<year>2012</year>). <article-title>Cognitive and subjective effects of mephedrone
and factors influencing use of a &#x02018;new legal high&#x02019;</article-title>. <source>Addiction</source>
<volume>107</volume>, <fpage>792</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="pmid">22257011</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><name><surname>Gage</surname><given-names>S</given-names></name>, <name><surname>Hickman</surname><given-names>M</given-names></name>, <name><surname>Heron</surname><given-names>J</given-names></name>, <name><surname>Munaf&#x000f2;</surname><given-names>M</given-names></name>, <name><surname>Lewis</surname><given-names>G</given-names></name>, <name><surname>Macleod</surname><given-names>J</given-names></name>, <name><surname>Zammit</surname><given-names>S</given-names></name> (<year>2014</year>). <article-title>Associations of cannabis and cigarette use
with psychotic experiences at age 18: findings from the Avon Longitudinal Study of
Parents and Children</article-title>. <source>Psychological Medicine</source>
<volume>44</volume>, <fpage>3435</fpage>&#x02013;<lpage>3444</lpage>.<pub-id pub-id-type="pmid">25066001</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><name><surname>Gamaleddin</surname><given-names>I</given-names></name>, <name><surname>Wertheim</surname><given-names>C</given-names></name>, <name><surname>Zhu</surname><given-names>AZ</given-names></name>, <name><surname>Coen</surname><given-names>KM</given-names></name>, <name><surname>Vemuri</surname><given-names>K</given-names></name>, <name><surname>Makryannis</surname><given-names>A</given-names></name>, <name><surname>Goldberg</surname><given-names>SR</given-names></name>, <name><surname>Le Foll</surname><given-names>B</given-names></name> (<year>2012</year>). <article-title>Cannabinoid receptor stimulation increases
motivation for nicotine and nicotine seeking</article-title>. <source>Addiction Biology</source>
<volume>17</volume>, <fpage>47</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">21521420</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><name><surname>Gossop</surname><given-names>M</given-names></name>, <name><surname>Darke</surname><given-names>S</given-names></name>, <name><surname>Griffiths</surname><given-names>P</given-names></name>, <name><surname>Hando</surname><given-names>J</given-names></name>, <name><surname>Powis</surname><given-names>B</given-names></name>, <name><surname>Hall</surname><given-names>W</given-names></name>, <name><surname>Strang</surname><given-names>J</given-names></name> (<year>1995</year>). <article-title>The Severity of Dependence Scale (SDS):
psychometric properties of the SDS in English and Australian samples of heroin, cocaine
and amphetamine users</article-title>. <source>Addiction</source>
<volume>90</volume>, <fpage>607</fpage>&#x02013;<lpage>614</lpage>.<pub-id pub-id-type="pmid">7795497</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><name><surname>Gray</surname><given-names>R</given-names></name>, <name><surname>Rajan</surname><given-names>AS</given-names></name>, <name><surname>Radcliffe</surname><given-names>KA</given-names></name>, <name><surname>Yakehiro</surname><given-names>M</given-names></name>, <name><surname>Dani</surname><given-names>JA</given-names></name> (<year>1996</year>). <article-title>Hippocampal synaptic transmission enhanced by
low concentrations of nicotine</article-title>. <source>Nature</source>
<volume>383</volume>, <fpage>713</fpage>&#x02013;<lpage>716</lpage>.<pub-id pub-id-type="pmid">8878480</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><name><surname>Gurillo</surname><given-names>P</given-names></name>, <name><surname>Jauhar</surname><given-names>S</given-names></name>, <name><surname>Murray</surname><given-names>RM</given-names></name>, <name><surname>Maccabe</surname><given-names>JH</given-names></name> (<year>2015</year>). <article-title>Does tobacco use cause psychosis? Systematic
review and meta-analysis</article-title>. <source>Lancet Psychiatry</source>
<volume>2</volume>, <fpage>718</fpage>&#x02013;<lpage>725</lpage>.<pub-id pub-id-type="pmid">26249303</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><name><surname>Hart</surname><given-names>CL</given-names></name>, <name><surname>Ilan</surname><given-names>AB</given-names></name>, <name><surname>Gevins</surname><given-names>A</given-names></name>, <name><surname>Gunderson</surname><given-names>EW</given-names></name>, <name><surname>Role</surname><given-names>K</given-names></name>, <name><surname>Colley</surname><given-names>J</given-names></name>, <name><surname>Foltin</surname><given-names>RW</given-names></name> (<year>2010</year>). <article-title>Neurophysiological and cognitive effects of
smoked marijuana in frequent users</article-title>. <source>Pharmacology Biochemistry
and Behavior</source>
<volume>96</volume>, <fpage>333</fpage>&#x02013;<lpage>341</lpage>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><name><surname>Hautus</surname><given-names>MJ</given-names></name> (<year>1995</year>). <article-title>Corrections for extreme proportions and their
biasing effects on estimated values ofd&#x02032;</article-title>. <source>Behavior Research
Methods, Instruments, &#x00026; Computers</source>
<volume>27</volume>, <fpage>46</fpage>&#x02013;<lpage>51</lpage>.</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><name><surname>Heatherton</surname><given-names>TF</given-names></name>, <name><surname>Kozlowski</surname><given-names>LT</given-names></name>, <name><surname>Frecker</surname><given-names>RC</given-names></name>, <name><surname>Fagerstrom</surname><given-names>KO</given-names></name> (<year>1991</year>). <article-title>The fagerstrom test for nicotine dependence: a
revision of the fagerstrom tolerance questionnaire</article-title>. <source>British
Journal of Addiction</source>
<volume>86</volume>, <fpage>1119</fpage>&#x02013;<lpage>1127</lpage>.<pub-id pub-id-type="pmid">1932883</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><name><surname>Heishman</surname><given-names>SJ</given-names></name>, <name><surname>Kleykamp</surname><given-names>BA</given-names></name>, <name><surname>Singleton</surname><given-names>EG</given-names></name> (<year>2010</year>). <article-title>Meta-analysis of the acute effects of nicotine
and smoking on human performance</article-title>. <source>Psychopharmacology
<italic>(</italic>Berl<italic>)</italic></source>
<volume>210</volume>, <fpage>453</fpage>&#x02013;<lpage>469</lpage>.<pub-id pub-id-type="pmid">20414766</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><name><surname>Herkenham</surname><given-names>M</given-names></name>, <name><surname>Lynn</surname><given-names>AB</given-names></name>, <name><surname>Little</surname><given-names>MD</given-names></name>, <name><surname>Johnson</surname><given-names>MR</given-names></name>, <name><surname>Melvin</surname><given-names>LS</given-names></name>, <name><surname>De Costa</surname><given-names>BR</given-names></name>, <name><surname>Rice</surname><given-names>KC</given-names></name> (<year>1990</year>). <article-title>Cannabinoid receptor localization in
brain</article-title>. <source>Proceedings of the National Academy of Sciences of the
United States of America</source>
<volume>87</volume>, <fpage>1932</fpage>&#x02013;<lpage>1936</lpage>.<pub-id pub-id-type="pmid">2308954</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><name><surname>Hindocha</surname><given-names>C</given-names></name>, <name><surname>Freeman</surname><given-names>TP</given-names></name>, <name><surname>Ferris</surname><given-names>JA</given-names></name>, <name><surname>Lynskey</surname><given-names>MT</given-names></name>, <name><surname>Winstock</surname><given-names>AR</given-names></name> (<year>2016</year>). <article-title>No smoke without tobacco: a global overview of
cannabis and tobacco routes of administration and their association with intention to
quit</article-title>. <source>Frontiers in Psychiatry</source>
<volume>7</volume>, <fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26903886</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><name><surname>Hindocha</surname><given-names>C</given-names></name>, <name><surname>Freeman</surname><given-names>TP</given-names></name>, <name><surname>Schafer</surname><given-names>G</given-names></name>, <name><surname>Gardener</surname><given-names>C</given-names></name>, <name><surname>Das</surname><given-names>RK</given-names></name>, <name><surname>Morgan</surname><given-names>CJ</given-names></name>, <name><surname>Curran</surname><given-names>HV</given-names></name> (<year>2015</year>). <article-title>Acute effects of delta-9-tetrahydrocannabinol,
cannabidiol and their combination on facial emotion recognition: a randomised,
double-blind, placebo-controlled study in cannabis users</article-title>.
<source>European Neuropsychopharmacology</source>
<volume>25</volume>, <fpage>325</fpage>&#x02013;<lpage>334</lpage>.<pub-id pub-id-type="pmid">25534187</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><name><surname>Hunault</surname><given-names>CC</given-names></name>, <name><surname>Mensinga</surname><given-names>TT</given-names></name>, <name><surname>Bocker</surname><given-names>KB</given-names></name>, <name><surname>Schipper</surname><given-names>CM</given-names></name>, <name><surname>Kruidenier</surname><given-names>M</given-names></name>, <name><surname>Leenders</surname><given-names>ME</given-names></name>, <name><surname>De Vries</surname><given-names>I</given-names></name>, <name><surname>Meulenbelt</surname><given-names>J</given-names></name> (<year>2009</year>). <article-title>Cognitive and psychomotor effects in males
after smoking a combination of tobacco and cannabis containing up to 69 mg
delta-9-tetrahydrocannabinol (THC)</article-title>. <source>Psychopharmacology
<italic>(</italic>Berl<italic>)</italic></source>
<volume>204</volume>, <fpage>85</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">19099294</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><name><surname>Jacobsen</surname><given-names>LK</given-names></name>, <name><surname>Pugh</surname><given-names>KR</given-names></name>, <name><surname>Constable</surname><given-names>RT</given-names></name>, <name><surname>Westerveld</surname><given-names>M</given-names></name>, <name><surname>Mencl</surname><given-names>WE</given-names></name> (<year>2007</year>). <article-title>Functional correlates of verbal memory
deficits emerging during nicotine withdrawal in abstinent adolescent cannabis
users</article-title>. <source>Biological Psychiatry</source>
<volume>61</volume>, <fpage>31</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">16631130</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><name><surname>Jarvik</surname><given-names>ME</given-names></name>, <name><surname>Madsen</surname><given-names>DC</given-names></name>, <name><surname>Olmstead</surname><given-names>RE</given-names></name>, <name><surname>Iwamoto-Schaap</surname><given-names>PN</given-names></name>, <name><surname>Elins</surname><given-names>JL</given-names></name>, <name><surname>Benowitz</surname><given-names>NL</given-names></name> (<year>2000</year>). <article-title>Nicotine blood levels and subjective craving
for cigarettes</article-title>. <source>Pharmacology, Biochemistry and Behavior</source>
<volume>66</volume>, <fpage>553</fpage>&#x02013;<lpage>558</lpage>.</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><name><surname>Koskinen</surname><given-names>J</given-names></name>, <name><surname>Lohonen</surname><given-names>J</given-names></name>, <name><surname>Koponen</surname><given-names>H</given-names></name>, <name><surname>Isohanni</surname><given-names>M</given-names></name>, <name><surname>Miettunen</surname><given-names>J</given-names></name> (<year>2010</year>). <article-title>Rate of cannabis use disorders in clinical
samples of patients with schizophrenia: a meta-analysis</article-title>.
<source>Schizophrenia Bulletin</source>
<volume>36</volume>, <fpage>1115</fpage>&#x02013;<lpage>1130</lpage>.<pub-id pub-id-type="pmid">19386576</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><name><surname>Kumari</surname><given-names>V</given-names></name>, <name><surname>Gray</surname><given-names>JA</given-names></name>, <name><surname>Mitterschiffthaler</surname><given-names>MT</given-names></name>, <name><surname>Das</surname><given-names>M</given-names></name>, <name><surname>Zachariah</surname><given-names>E</given-names></name>, <name><surname>Vythelingum</surname><given-names>GN</given-names></name>, <name><surname>Williams</surname><given-names>SC</given-names></name>, <name><surname>Simmons</surname><given-names>A</given-names></name>, <name><surname>Sharma</surname><given-names>T</given-names></name> (<year>2003</year>). <article-title>Cognitive effects of nicotine in humans: an
fMRI study</article-title>. <source>NeuroImage</source>
<volume>19</volume>, <fpage>1002</fpage>&#x02013;<lpage>1013</lpage>.<pub-id pub-id-type="pmid">12880828</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><name><surname>Lawn</surname><given-names>W</given-names></name>, <name><surname>Freeman</surname><given-names>TP</given-names></name>, <name><surname>Pope</surname><given-names>RA</given-names></name>, <name><surname>Joye</surname><given-names>A</given-names></name>, <name><surname>Harvey</surname><given-names>L</given-names></name>, <name><surname>Hindocha</surname><given-names>C</given-names></name>, <name><surname>Mokrysz</surname><given-names>C</given-names></name>, <name><surname>Moss</surname><given-names>A</given-names></name>, <name><surname>Wall</surname><given-names>MB</given-names></name>, <name><surname>Bloomfield</surname><given-names>MA</given-names></name> (<year>2016</year>). <article-title>Acute and chronic effects of cannabinoids on
effort-related decision-making and reward learning: an evaluation of the cannabis
&#x02018;amotivational'hypotheses</article-title>. <source>Psychopharmacology</source>
<volume>233</volume>, <fpage>3537</fpage>&#x02013;<lpage>3552</lpage>.<pub-id pub-id-type="pmid">27585792</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><name><surname>Le Foll</surname><given-names>B</given-names></name>, <name><surname>Goldberg</surname><given-names>SR</given-names></name> (<year>2004</year>). <article-title>Rimonabant, a CB1 antagonist, blocks
nicotine-conditioned place preferences</article-title>. <source>Neuroreport</source>
<volume>15</volume>, <fpage>2139</fpage>&#x02013;<lpage>2143</lpage>.<pub-id pub-id-type="pmid">15486497</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><name><surname>Levin</surname><given-names>ED</given-names></name>, <name><surname>Mcclernon</surname><given-names>FJ</given-names></name>, <name><surname>Rezvani</surname><given-names>AH</given-names></name> (<year>2006</year>). <article-title>Nicotinic effects on cognitive function:
behavioral characterization, pharmacological specification, and anatomic
localization</article-title>. <source>Psychopharmacology
<italic>(</italic>Berl<italic>)</italic></source>
<volume>184</volume>, <fpage>523</fpage>&#x02013;<lpage>539</lpage>.<pub-id pub-id-type="pmid">16220335</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><name><surname>Levin</surname><given-names>ED</given-names></name>, <name><surname>Simon</surname><given-names>BB</given-names></name> (<year>1998</year>). <article-title>Nicotinic acetylcholine involvement in
cognitive function in animals</article-title>. <source>Psychopharmacology</source>
<volume>138</volume>, <fpage>217</fpage>&#x02013;<lpage>230</lpage>.<pub-id pub-id-type="pmid">9725745</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><name><surname>Marteau</surname><given-names>TM</given-names></name>, <name><surname>Bekker</surname><given-names>H</given-names></name> (<year>1992</year>). <article-title>The development of a six-item short-form of
the state scale of the Spielberger State-Trait Anxiety Inventory (STAI)</article-title>.
<source>British Journal of Clinical Psychology</source>
<volume>31</volume>, <fpage>301</fpage>&#x02013;<lpage>306</lpage>.<pub-id pub-id-type="pmid">1393159</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><name><surname>Mason</surname><given-names>OJ</given-names></name>, <name><surname>Morgan</surname><given-names>CJ</given-names></name>, <name><surname>Stefanovic</surname><given-names>A</given-names></name>, <name><surname>Curran</surname><given-names>HV</given-names></name> (<year>2008</year>). <article-title>The psychotomimetic states inventory (PSI):
measuring psychotic-type experiences from ketamine and cannabis</article-title>.
<source>Schizophrenia Research</source>
<volume>103</volume>, <fpage>138</fpage>&#x02013;<lpage>142</lpage>.<pub-id pub-id-type="pmid">18387788</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><name><surname>Mendelson</surname><given-names>JH</given-names></name>, <name><surname>Sholar</surname><given-names>MB</given-names></name>, <name><surname>Goletiani</surname><given-names>N</given-names></name>, <name><surname>Siegel</surname><given-names>AJ</given-names></name>, <name><surname>Mello</surname><given-names>NK</given-names></name> (<year>2005</year>). <article-title>Effects of low- and high-nicotine cigarette
smoking on mood states and the HPA axis in men</article-title>.
<source>Neuropsychopharmacology</source>
<volume>30</volume>, <fpage>1751</fpage>&#x02013;<lpage>1763</lpage>.<pub-id pub-id-type="pmid">15870834</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><name><surname>Mendelson</surname><given-names>JH</given-names></name>, <name><surname>Sholar</surname><given-names>MB</given-names></name>, <name><surname>Mutschler</surname><given-names>NH</given-names></name>, <name><surname>Jaszyna-Gasior</surname><given-names>M</given-names></name>, <name><surname>Goletiani</surname><given-names>NV</given-names></name>, <name><surname>Siegel</surname><given-names>AJ</given-names></name>, <name><surname>Mello</surname><given-names>NK</given-names></name> (<year>2003</year>). <article-title>Effects of intravenous cocaine and cigarette
smoking on luteinizing hormone, testosterone, and prolactin in men</article-title>.
<source>Journal of Pharmacology and Experimental Therapeutics</source>
<volume>307</volume>, <fpage>339</fpage>&#x02013;<lpage>348</lpage>.<pub-id pub-id-type="pmid">12893845</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><name><surname>Mokrysz</surname><given-names>C</given-names></name>, <name><surname>Freeman</surname><given-names>T</given-names></name>, <name><surname>Korkki</surname><given-names>S</given-names></name>, <name><surname>Griffiths</surname><given-names>K</given-names></name>, <name><surname>Curran</surname><given-names>H</given-names></name> (<year>2016</year>). <article-title>Are adolescents more vulnerable to the harmful
effects of cannabis than adults; A placebo-controlled study in human
males</article-title>. <source>Translational Psychiatry</source>
<volume>6</volume>, <fpage>e961</fpage>.<pub-id pub-id-type="pmid">27898071</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>TH</given-names></name>, <name><surname>Zammit</surname><given-names>S</given-names></name>, <name><surname>Lingford-Hughes</surname><given-names>A</given-names></name>, <name><surname>Barnes</surname><given-names>TR</given-names></name>, <name><surname>Jones</surname><given-names>PB</given-names></name>, <name><surname>Burke</surname><given-names>M</given-names></name>, <name><surname>Lewis</surname><given-names>G</given-names></name> (<year>2007</year>). <article-title>Cannabis use and risk of psychotic or
affective mental health outcomes: a systematic review</article-title>. <source>Lancet</source>
<volume>370</volume>, <fpage>319</fpage>&#x02013;<lpage>328</lpage>.<pub-id pub-id-type="pmid">17662880</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><name><surname>Morgan</surname><given-names>CJA</given-names></name>, <name><surname>Dodds</surname><given-names>C</given-names></name>, <name><surname>Furby</surname><given-names>H</given-names></name>, <name><surname>Pepper</surname><given-names>F</given-names></name>, <name><surname>Fam</surname><given-names>J</given-names></name>, <name><surname>Freeman</surname><given-names>T</given-names></name>, <name><surname>Hughes</surname><given-names>E</given-names></name>, <name><surname>Doeller</surname><given-names>C</given-names></name>, <name><surname>King</surname><given-names>J</given-names></name>, <name><surname>Stone</surname><given-names>J</given-names></name>, <name><surname>Howes</surname><given-names>O</given-names></name> (<year>2014</year>). <article-title>Long-term heavy ketamine use is associated
with spatial memory impairment and altered hippocampal activation</article-title>.
<source>Frontiers in Psychiatry</source>
<volume>5</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">24478729</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><name><surname>Morrison</surname><given-names>P</given-names></name>, <name><surname>Zois</surname><given-names>V</given-names></name>, <name><surname>Mckeown</surname><given-names>D</given-names></name>, <name><surname>Lee</surname><given-names>T</given-names></name>, <name><surname>Holt</surname><given-names>D</given-names></name>, <name><surname>Powell</surname><given-names>J</given-names></name>, <name><surname>Kapur</surname><given-names>S</given-names></name>, <name><surname>Murray</surname><given-names>R</given-names></name> (<year>2009</year>). <article-title>The acute effects of synthetic intravenous &#x00394;
9-tetrahydrocannabinol on psychosis, mood and cognitive functioning</article-title>.
<source>Psychological Medicine</source>
<volume>39</volume>, <fpage>1607</fpage>&#x02013;<lpage>1616</lpage>.<pub-id pub-id-type="pmid">19335936</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><name><surname>Penetar</surname><given-names>DM</given-names></name>, <name><surname>Kouri</surname><given-names>EM</given-names></name>, <name><surname>Gross</surname><given-names>MM</given-names></name>, <name><surname>Mccarthy</surname><given-names>EM</given-names></name>, <name><surname>Rhee</surname><given-names>CK</given-names></name>, <name><surname>Peters</surname><given-names>EN</given-names></name>, <name><surname>Lukas</surname><given-names>SE</given-names></name> (<year>2005</year>). <article-title>Transdermal nicotine alters some of
marihuana's effects in male and female volunteers</article-title>. <source>Drug and
Alcohol Dependence</source>
<volume>79</volume>, <fpage>211</fpage>&#x02013;<lpage>223</lpage>.<pub-id pub-id-type="pmid">16002030</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><name><surname>Picciotto</surname><given-names>MR</given-names></name>, <name><surname>Caldarone</surname><given-names>BJ</given-names></name>, <name><surname>King</surname><given-names>SL</given-names></name>, <name><surname>Zachariou</surname><given-names>V</given-names></name> (<year>2000</year>). <article-title>Nicotinic receptors in the brain: links
between molecular biology and behavior</article-title>. <source>Neuropsychopharmacology</source>
<volume>22</volume>, <fpage>451</fpage>&#x02013;<lpage>465</lpage>.<pub-id pub-id-type="pmid">10731620</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><name><surname>Rabin</surname><given-names>RA</given-names></name>, <name><surname>George</surname><given-names>TP</given-names></name> (<year>2015</year>). <article-title>A review of co-morbid tobacco and cannabis use
disorders: possible mechanisms to explain high rates of co-use</article-title>.
<source>American Journal on Addictions</source>
<volume>24</volume>, <fpage>105</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">25662704</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><name><surname>Raine</surname><given-names>A</given-names></name> (<year>1991</year>). <article-title>The SPQ: a scale for the assessment of
schizotypal personality based on DSM-III-R criteria</article-title>.
<source>Schizophrenia Bulletin</source>
<volume>17</volume>, <fpage>555</fpage>.<pub-id pub-id-type="pmid">1805349</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><name><surname>Ramaekers</surname><given-names>JG</given-names></name>, <name><surname>Kauert</surname><given-names>G</given-names></name>, <name><surname>Theunissen</surname><given-names>EL</given-names></name>, <name><surname>Toennes</surname><given-names>SW</given-names></name>, <name><surname>Moeller</surname><given-names>ML</given-names></name> (<year>2009</year>). <article-title>Neurocognitive performance during acute THC
intoxication in heavy and occasional cannabis users</article-title>. <source>Journal of
Psychopharmacology</source>
<volume>23</volume>, <fpage>266</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="pmid">18719045</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><name><surname>Rowell</surname><given-names>PP</given-names></name>, <name><surname>Carr</surname><given-names>LA</given-names></name>, <name><surname>Garner</surname><given-names>AC</given-names></name> (<year>1987</year>). <article-title>Stimulation of [3H] dopamine release by
nicotine in rat nucleus accumbens</article-title>. <source>Journal of Neurochemistry</source>
<volume>49</volume>, <fpage>1449</fpage>&#x02013;<lpage>1454</lpage>.<pub-id pub-id-type="pmid">2889800</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><name><surname>Schuster</surname><given-names>RM</given-names></name>, <name><surname>Crane</surname><given-names>NA</given-names></name>, <name><surname>Mermelstein</surname><given-names>R</given-names></name>, <name><surname>Gonzalez</surname><given-names>R</given-names></name> (<year>2015</year>). <article-title>Tobacco may mask poorer episodic memory among
young adult cannabis users</article-title>. <source>Neuropsychology</source>
<volume>29</volume>, <fpage>759</fpage>&#x02013;<lpage>766</lpage>.<pub-id pub-id-type="pmid">25558879</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><name><surname>Schuster</surname><given-names>RM</given-names></name>, <name><surname>Mermelstein</surname><given-names>RJ</given-names></name>, <name><surname>Hedeker</surname><given-names>D</given-names></name> (<year>2016</year>). <article-title>Ecological momentary assessment of working
memory under conditions of simultaneous Marijuana and tobacco use</article-title>.
<source>Addiction</source>
<volume>8</volume>, <fpage>1466</fpage>&#x02013;<lpage>1476</lpage>.</mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><name><surname>Shoaib</surname><given-names>M</given-names></name> (<year>2008</year>). <article-title>The cannabinoid antagonist AM251 attenuates
nicotine self-administration and nicotine-seeking behaviour in rats</article-title>.
<source>Neuropharmacology</source>
<volume>54</volume>, <fpage>438</fpage>&#x02013;<lpage>444</lpage>.<pub-id pub-id-type="pmid">18054052</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><name><surname>Snodgrass</surname><given-names>JG</given-names></name>, <name><surname>Corwin</surname><given-names>J</given-names></name> (<year>1988</year>). <article-title>Pragmatics of measuring recognition memory:
applications to dementia and amnesia</article-title>. <source>Journal of Experimental
Psychology: General</source>
<volume>117</volume>, <fpage>34</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">2966230</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><name><surname>Spielberger</surname><given-names>CD</given-names></name>, <name><surname>Gorsuch</surname><given-names>RL</given-names></name>, <name><surname>Lushene</surname><given-names>RE</given-names></name>, <name><surname>Vagg</surname><given-names>PR</given-names></name> (<year>1970</year>). <article-title>State-trait anxiety inventory
(STAI)</article-title>. <source>BiB</source>
<volume>2010</volume>, <fpage>180</fpage>.</mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><name><surname>Stanislaw</surname><given-names>H</given-names></name>, <name><surname>Todorov</surname><given-names>N</given-names></name> (<year>1999</year>). <article-title>Calculation of signal detection theory
measures</article-title>. <source>Behavior Research Methods, Instruments, &#x00026;
Computers</source>
<volume>31</volume>, <fpage>137</fpage>&#x02013;<lpage>149</lpage>.</mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><name><surname>Valjent</surname><given-names>E</given-names></name>, <name><surname>Mitchell</surname><given-names>JM</given-names></name>, <name><surname>Besson</surname><given-names>MJ</given-names></name>, <name><surname>Caboche</surname><given-names>J</given-names></name>, <name><surname>Maldonado</surname><given-names>R</given-names></name> (<year>2002</year>). <article-title>Behavioural and biochemical evidence for
interactions between &#x00394;9-tetrahydrocannabinol and nicotine</article-title>.
<source>British Journal of Pharmacology</source>
<volume>135</volume>, <fpage>564</fpage>&#x02013;<lpage>578</lpage>.<pub-id pub-id-type="pmid">11815392</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><name><surname>Van Der Pol</surname><given-names>P</given-names></name>, <name><surname>Liebregts</surname><given-names>N</given-names></name>, <name><surname>Brunt</surname><given-names>T</given-names></name>, <name><surname>Van Amsterdam</surname><given-names>J</given-names></name>, <name><surname>De Graaf</surname><given-names>R</given-names></name>, <name><surname>Korf</surname><given-names>DJ</given-names></name>, <name><surname>Van Den Brink</surname><given-names>W</given-names></name>, <name><surname>Van Laar</surname><given-names>M</given-names></name> (<year>2014</year>). <article-title>Cross-sectional and prospective relation of
cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological
study</article-title>. <source>Addiction</source>
<volume>109</volume>, <fpage>1101</fpage>&#x02013;<lpage>1109</lpage>.<pub-id pub-id-type="pmid">24628797</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><name><surname>Van Gastel</surname><given-names>WA</given-names></name>, <name><surname>Maccabe</surname><given-names>JH</given-names></name>, <name><surname>Schubart</surname><given-names>CD</given-names></name>, <name><surname>Vreeker</surname><given-names>A</given-names></name>, <name><surname>Tempelaar</surname><given-names>W</given-names></name>, <name><surname>Kahn</surname><given-names>RS</given-names></name>, <name><surname>Boks</surname><given-names>MPM</given-names></name> (<year>2013</year>). <article-title>Cigarette smoking and cannabis use are equally
strongly associated with psychotic-like experiences: a cross-sectional study in 1929
young adults</article-title>. <source>Psychological Medicine</source>
<volume>43</volume>, <fpage>2393</fpage>&#x02013;<lpage>2401</lpage>.<pub-id pub-id-type="pmid">23414608</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="book"><name><surname>Wilson</surname><given-names>BA</given-names></name>, <name><surname>Cockburn</surname><given-names>J</given-names></name>, <name><surname>Baddeley</surname><given-names>AD</given-names></name> (<year>1991</year>). <source>The Rivermead Behavioural Memory Test</source>.
<publisher-name>Thames Valley Test Company</publisher-name>:
<publisher-loc>Suffolk</publisher-loc>.</mixed-citation></ref></ref-list></back></article>